Stephen T. Isaacs Sells 40,000 Shares of Aduro BioTech Inc (ADRO) Stock

Aduro BioTech Inc (NASDAQ:ADRO) insider Stephen T. Isaacs sold 40,000 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $9.38, for a total value of $375,200.00. Following the transaction, the insider now directly owns 213,921 shares in the company, valued at $2,006,578.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of Aduro BioTech Inc (ADRO) opened at $8.60 on Wednesday. Aduro BioTech Inc has a 1-year low of $6.01 and a 1-year high of $14.05.

Aduro BioTech (NASDAQ:ADRO) last announced its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). The company had revenue of $3.79 million for the quarter, compared to analysts’ expectations of $4.04 million. Aduro BioTech had a negative net margin of 548.92% and a negative return on equity of 39.28%. Aduro BioTech’s quarterly revenue was up .0% compared to the same quarter last year. During the same period last year, the firm earned ($0.54) earnings per share. sell-side analysts forecast that Aduro BioTech Inc will post -1.28 earnings per share for the current year.

A number of equities analysts have recently issued reports on ADRO shares. Oppenheimer started coverage on Aduro BioTech in a research report on Monday, October 30th. They set a “buy” rating and a $15.00 price target on the stock. HC Wainwright set a $18.00 price target on Aduro BioTech and gave the stock a “buy” rating in a research report on Tuesday, October 17th. William Blair reaffirmed an “outperform” rating on shares of Aduro BioTech in a research report on Monday, October 2nd. Finally, BidaskClub downgraded Aduro BioTech from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $19.14.

Institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. grew its holdings in shares of Aduro BioTech by 283.7% during the second quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock valued at $4,244,000 after buying an additional 275,295 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Aduro BioTech by 5.7% during the first quarter. Schwab Charles Investment Management Inc. now owns 145,112 shares of the biotechnology company’s stock valued at $1,560,000 after buying an additional 7,812 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Aduro BioTech by 2.1% during the first quarter. Vanguard Group Inc. now owns 2,382,916 shares of the biotechnology company’s stock valued at $25,617,000 after buying an additional 48,840 shares during the last quarter. PDT Partners LLC purchased a new stake in shares of Aduro BioTech during the second quarter valued at $570,000. Finally, Artal Group S.A. grew its holdings in shares of Aduro BioTech by 100.0% during the third quarter. Artal Group S.A. now owns 200,000 shares of the biotechnology company’s stock valued at $2,130,000 after buying an additional 100,000 shares during the last quarter. 45.19% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Stephen T. Isaacs Sells 40,000 Shares of Aduro BioTech Inc (ADRO) Stock” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://stocknewstimes.com/2017/12/06/stephen-t-isaacs-sells-40000-shares-of-aduro-biotech-inc-adro-stock.html.

Aduro BioTech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply